Klaus Schmierer

41PUBLICATIONS
79CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Software quality, processes and metricsReinforcement learningCancer therapy (excl. chemotherapy and radiation therapy)People with disability
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Oct 17, 2026
Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies.

|Aug 28, 2026
Diagnosing multiple sclerosis: implementation and unintended effects of the 2024 McDonald criteria.

|Aug 04, 2026
Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.

|Jul 06, 2026
Transfusion-Associated Graft-Versus-Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?

|May 01, 2026
Understanding the Unmet Needs of People with MS at Diagnosis and Throughout Their Care Journey: Insights from a Survey-Based Study.

|Aug 04, 2025
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.

Klaus Schmierer, Heinz Wiendl, Frederik Barkhof

Pageof 7

Frequent Collaborators

7 joint publications

David Baker

5 joint publications

Emma C Tallantyre

5 joint publications

Kimberley Allen-Philbey

3 joint publications

Gavin Giovannoni